Kardigan, Inc. KARD
14.12 USD -1.56 (-9.95%)
At closeNov 12, 2026, 4:26 PM EST
14.12 0.00 0.00%
After hours · Nov 12, 4:26 PM ET
14.11 Day range 15.85
12.23 52-week range 27.00
- YTD
- -35.82%
- 1 year
- -35.82%
News
benzinga.com Kardigan Q3 EPS $(0.64) Beats $(0.77) Estimate Kardigan (NASDAQ:KARD) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.77) by 16.88 percent. This is a 85.55 percent increase over losses of $(4.43)…
businesswire.com Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan today reported financial results for the third quarter ended September 30, 2026, and provided recent…
businesswire.com Kardigan to Participate in the Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan today announced that the company will participate in a fireside chat at the 2026 Jefferies London…
seekingalpha.com Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript
marketbeat.com Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results Kardigan NASDAQ: KARD said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled and that it will assess the study's primary endpoint at 48 weeks, rather than 24…
benzinga.com Kardigan Completes Enrollment In Phase 2b KATALYST-AV Trial Of Ataciguat In People With Aortic Stenosis Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function; topline data expected 2H 2027Novel…
businesswire.com Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic…
benzinga.com This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Analysts initiated coverage: Neutral on KEEL ($2), Buy on PTN ($12), FRVO ($17) and YARW ($60).
benzinga.com This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday Analysts initiated coverage: BMO rated Astera Labs Outperform with a $375 target; Citi rated ATI Buy with a $229 target.
benzinga.com This Lockheed Martin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage on MSGR (Outperform), NTSK (Overweight, $28), KARD (Buy, $42).
benzinga.com HC Wainwright & Co. Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $42 HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Kardigan (NASDAQ:KARD) with a Buy rating and announces Price Target of $42.
benzinga.com This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
247wallst.com Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Boston Scientific, eBay, Fervo Energy, Fortinet, Hilton Worldwide Holdings, Lennox International, Palantir Technologies, and More Pre-Market Stock Futures: Futures are trading lower after a solid day for the stock market, as the interest-rate scenario played out as we (and most across Wall Street) predicted, with the Federal…
benzinga.com Cantor Fitzgerald Initiates Coverage On Kardigan with Overweight Rating, Announces Price Target of $50 Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Kardigan (NASDAQ:KARD) with a Overweight rating and announces Price Target of $50.
benzinga.com This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for CleanSpark, Constellation Energy and Atrium; Outperform for Kardigan; Neutral for Northwest Natural.- benzinga.com Baird Initiates Coverage On Kardigan with Outperform Rating, Announces Price Target of $43 Baird analyst Jack Allen initiates coverage on Kardigan (NASDAQ:KARD) with a Outperform rating and announces Price Target of $43.
- benzinga.com UBS Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $25 UBS analyst Alice Nettleton initiates coverage on Kardigan (NASDAQ:KARD) with a Buy rating and announces Price Target of $25.
businesswire.com Kardigan Announces Appointment of Kristin Reinke to its Board of Directors SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair…
defenseworld.net Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts Shares of Kardigan, Inc. (NASDAQ: KARD - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat.com reports.…
seekingalpha.com Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of…
businesswire.com Kardigan to Present at Two September Investor Conferences SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and…- benzinga.com JP Morgan Maintains Overweight on Kardigan, Lowers Price Target to $46 JP Morgan analyst Anupam Rama maintains Kardigan (NASDAQ:KARD) with a Overweight and lowers the price target from $51 to $46.
gurufocus.com Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates Kardiganâ¢, Inc. (Nasdaq: KARD) (âKardiganâ or âthe Companyâ), a clinical-stage precision therapeutics company developing medicines that target the roo
benzinga.com Kardigan Q2 EPS $(4.61) Misses $(0.71) Estimate Kardigan (NASDAQ:KARD) reported quarterly losses of $(4.61) per share which missed the analyst consensus estimate of $(0.71) by 549.3 percent. This is a 0.65 percent increase over losses of $(4.64)…
businesswire.com Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and…- benzinga.com TD Cowen Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $46 TD Cowen analyst Ritu Baral initiates coverage on Kardigan (NASDAQ:KARD) with a Buy rating and announces Price Target of $46.
benzinga.com Leerink Partners Initiates Coverage On Kardigan with Outperform Rating, Announces Price Target of $37 Leerink Partners analyst Roanna Ruiz initiates coverage on Kardigan (NASDAQ:KARD) with a Outperform rating and announces Price Target of $37.
benzinga.com This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Wall Street analysts changed outlook on top stocks. To see all changes, visit the analyst ratings page. FAST stock has a Buy rating with $55 PT.
benzinga.com JP Morgan Initiates Coverage On Kardigan with Overweight Rating, Announces Price Target of $51 JP Morgan analyst Anupam Rama initiates coverage on Kardigan (NASDAQ:KARD) with a Overweight rating and announces Price Target of $51.
benzinga.com Jefferies Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $40 Jefferies analyst Dennis Ding initiates coverage on Kardigan (NASDAQ:KARD) with a Buy rating and announces Price Target of $40.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares…
businesswire.com Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.
reuters.com Kardigan rises in Nasdaq debut after upsized $400 million IPO Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering.
businesswire.com Kardigan Announces Pricing of Upsized Initial Public Offering SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines…
reuters.com Heart drug developer Kardigan targets $1.4 billion valuation in US IPO Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the drug developer said on Thursday.
seekingalpha.com Kardigan Begins Process For IPO On Cardiovascular Treatments Promise Kardigan, Inc. (KARD) is a clinical-stage biopharma targeting various cardiovascular disease treatments with a pipeline led by Danicamtiv, now in Phase 2b/3 trials. KARD leverages its Prolario AI…